⌕
Vertex Pharmaceuticals · VRTX · Nasdaq
Tenet 55 · Mixed
Compare
$534.20−0.67%At closeTenet 55 · Mixed
$534.20−3.59 (−0.67%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$530.05−4.15 (−0.78%)
After hours: Nov 17, 2026, 7:59 PM ET

Vertex Pharmaceuticals (VRTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is VRTX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● The Motley FoolNov 17, 2026 · 18:27 ET
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expan…

VRTX −0.7% todayRead at source ↗
● Seeking AlphaNov 17, 2026 · 15:03 ET
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

VRTX −0.7% todayRead at source ↗
● Defense WorldNov 17, 2026 · 08:01 ETEARNINGS EXPECTED BY FEB 8
5,362 Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banco Santander S.A.

Banco Santander S.A. raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 5.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission.…

VRTX −0.7% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 08:12 ET
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript…

VRTX −0.7% todayRead at source ↗
● The Motley FoolNov 13, 2026 · 17:42 ET
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain m…

VRTX −0.7% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 17:26 ET
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

VRTX −0.7% todayRead at source ↗
● Defense WorldNov 10, 2026 · 04:03 ETEARNINGS EXPECTED BY FEB 8
Vertex Pharmaceuticals Incorporated $VRTX Stock Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 11.7% during a recent quarter, according to the company in its most recent Form 13F filing wit…

VRTX −0.7% todayRead at source ↗
● Defense WorldNov 9, 2026 · 04:01 ETEARNINGS EXPECTED BY FEB 8
1,797 Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Ethic Inc.

Ethic Inc. lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.6% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 22,744 shares of the phar…

VRTX −0.7% todayRead at source ↗
● The Motley FoolNov 5, 2026 · 16:47 ET
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years

Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.…

VRTX −0.7% todayRead at source ↗
● Defense WorldNov 5, 2026 · 05:01 ETEARNINGS EXPECTED BY FEB 8
Associated Banc Corp Purchases 5,962 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Associated Banc Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. Th…

VRTX −0.7% todayRead at source ↗
● Defense WorldNov 4, 2026 · 06:52 ETEARNINGS EXPECTED BY FEB 8
Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by AIA Group Ltd

AIA Group Ltd reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 23.8% in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm …

VRTX −0.7% todayRead at source ↗
● FXEmpireNov 4, 2026 · 06:22 ETEARNINGS EXPECTED BY FEB 8
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance

VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.…

VRTX −0.7% todayRead at source ↗
● Defense WorldNov 4, 2026 · 04:30 ETEARNINGS EXPECTED BY FEB 8
Aware Super Pty Ltd as trustee of Aware Super Acquires 11,017 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Aware Super Pty Ltd as trustee of Aware Super boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 121.9% in a recent quarter, according to the company in its most recent Form 13F filin…

VRTX −0.7% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 8
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.…

VRTX −0.7% todayRead at source ↗
● BenzingaNov 3, 2026 · 08:15 ETEARNINGS EXPECTED BY FEB 8
Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.…

VRTX −0.7% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 00:48 ETEARNINGS EXPECTED BY FEB 8
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript

Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director…

VRTX −0.7% todayRead at source ↗
● MarketBeatNov 2, 2026 · 21:15 ETEARNINGS EXPECTED BY FEB 8
Vertex Pharmaceuticals Q3 Earnings Call Highlights

Vertex Pharmaceuticals NASDAQ: VRTX reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURN…

VRTX −0.7% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 18:30 ETEARNINGS EXPECTED BY FEB 8
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street est…

VRTX −0.7% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 18:25 ETEARNINGS EXPECTED BY FEB 8
Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92 per share. This compares to earnings of $4.8 per share a year ago.…

VRTX −0.7% todayRead at source ↗
● The Motley FoolNov 2, 2026 · 16:30 ETEARNINGS EXPECTED BY FEB 8
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Alyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise. Heavy spending on new launches and the Crinetics deal kept profit from rising with sales.…

VRTX −0.7% todayRead at source ↗
● Business WireNov 2, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Vertex Reports Third Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. “V…

VRTX −0.7% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 10:16 ETEARNINGS EXPECTED BY FEB 8
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.…

VRTX −0.7% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 10:01 ET
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.…

VRTX −0.7% todayRead at source ↗
● Business WireOct 23, 2026 · 13:42 ETEARNINGS EXPECTED BY FEB 8
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these…

VRTX −0.7% todayRead at source ↗
● Business WireOct 20, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vertex Appoints Daniel Brennan to its Board of Directors

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years …

VRTX −0.7% todayRead at source ↗
● Business WireOct 9, 2026 · 13:15 ETCOMPANY'S OWN WORDS
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highligh…

VRTX −0.7% todayRead at source ↗
● Business WireOct 7, 2026 · 16:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Vertex to Announce Third Quarter 2026 Financial Results November 2nd

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a con…

VRTX −0.7% todayRead at source ↗
● Business WireSep 22, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest p…

VRTX −0.7% todayRead at source ↗
● Business WireSep 1, 2026 · 09:03 ETCOMPANY'S OWN WORDS
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company …

VRTX −0.7% todayRead at source ↗
● Business WireAug 26, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Vertex to Participate in Upcoming September Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Mani…

VRTX −0.7% todayRead at source ↗
● Business WireAug 17, 2026 · 12:57 ET
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals…

VRTX −0.7% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 8. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA36−0.4%
DLB3−3.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just VRTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.